Fundraising FoxTherabron Therapeutics
Rockville, US · Delaware corporation
Find your way into Therabron Therapeutics
Sign up to see every warm intro you have to Therabron Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Therabron Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Founders & leadership
AL
Aprile L. Pilon-ClaytonChief Executive Officer and Director of Issuer
AP
Aprile Pilon-ClaytonCo-founder
TM
Thomas MillerPresident of IssuerThomas Miller holds a B.S. in Chemistry and Mathematics from Texas A&M University and a Ph.D. in Theoretical Chemistry from the University of Oxford. He spent over a decade as a tenured professor at Caltech, where he published more than 140 peer-reviewed articles and patents, before co-founding Iambic Therapeutics in 2020 as its CEO to develop an AI-driven drug discovery platform.
BM
Blanche M. JohnsonSecretary and Director of Issuer
Board
JZ
Jeffrey ZellBoard director
VP
Vinzenz PloererBoard director
CC
Christine CoppleBoard director
Reported raises · per SEC filings
Form D private placements$15M disclosed across 3 rounds · 2014–2016
▶$2.3MraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
▶$2.3MraisedDec 2016 · 4 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Todd BradyDirector
- Aprile L Pilon-ClaytonExecutive Officer, Director
- Vinzenz PloererExecutive Officer, Director
- Eric RichmanDirector
- Jeffrey ZellDirector
- Blanche M JohnsonDirector
- Linda ChangExecutive Officer
- Offering amount
- $6M
- Amount sold
- $2.3M
- First sale
- Dec 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$5.5MraisedNov 2015 · 1 investors · BiotechnologyRule 506(b)
▶$5.5MraisedNov 2015 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey ZellDirector
- Vinzenz PloererDirector
- Thomas MillerExecutive Officer
- Aprile L. Pilon-ClaytonExecutive Officer, Director
- Christine CoppleDirector
- Blanche M. JohnsonExecutive Officer, Director
- Offering amount
- $6.7M
- Amount sold
- $5.5M
- First sale
- Nov 2015
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$7.2MraisedJun 2014 · 11 investors · BiotechnologyRule 506(b)
▶$7.2MraisedJun 2014 · 11 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey ZellDirector
- Blanche JohnsonExecutive Officer, Director
- Aprile Pilon-ClaytonExecutive Officer, Director, Promoter
- Vinzenz PloererDirector
- Christine CoppleDirector
- Offering amount
- $7.2M
- Amount sold
- $7.2M
- Minimum investment
- $2K
- Proceeds to insiders
- $187.2K
- First sale
- Jun 2014
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- Who founded Therabron Therapeutics?
- Therabron Therapeutics was founded by Aprile L. Pilon-Clayton, Aprile Pilon-Clayton.
- How much funding has Therabron Therapeutics raised?
- Therabron Therapeutics has disclosed $15M raised across 3 rounds.
- Where is Therabron Therapeutics headquartered?
- Therabron Therapeutics is headquartered in Rockville, US.